Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline plc    GSK   GB0009252882

GLAXOSMITHKLINE PLC

(GSK)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
10/16/2020 10/19/2020 10/20/2020 10/21/2020 10/22/2020 Date
1410(c) 1396.6(c) 1380.2(c) 1353.6(c) 1336.156 Last
8 030 793 3 685 439 5 584 756 7 961 446 1 908 759 Volume
+2.46% -0.95% -1.17% -1.93% -1.29% Change
More quotes
Financials
Sales 2020 34 653 M 45 500 M 45 500 M
Net income 2020 4 791 M 6 290 M 6 290 M
Net Debt 2020 22 730 M 29 844 M 29 844 M
P/E ratio 2020 14,0x
Yield 2020 5,91%
Sales 2021 35 751 M 46 941 M 46 941 M
Net income 2021 4 326 M 5 679 M 5 679 M
Net Debt 2021 20 973 M 27 538 M 27 538 M
P/E ratio 2021 15,7x
Yield 2021 5,91%
Capitalization 67 378 M 88 545 M 88 468 M
EV / Sales 2020 2,60x
EV / Sales 2021 2,47x
Nbr of Employees 99 437
Free-Float 91,3%
More Financials
Company
GlaxoSmithkline plc is the world's No. 2 pharmaceutical group. Net sales break down by family of products as follows: - pharmaceutical products (52%): intended for respiratory diseases (67.5% of net sales), HIV infection (27.7%), immune system disorders (3.5%) ) and cancer (1,3%); - OTC and parapharmaceutical medicine (26.7%); - vaccines (21.2%); - other (0.1%). Net sales are distributed geographically as... 
Sector
Pharmaceuticals
Calendar
10/28 | 07:00amEarnings Release
More about the company
Notations Surperformance© of GlaxoSmithKline plc
Trading Rating : Investor Rating :
More Ratings
All news about GLAXOSMITHKLINE PLC
03:10aGLAXOSMITHKLINE : ViiV Healthcare presents positive new findings from two studie..
PU
03:10aGLAXOSMITHKLINE : ViiV Healthcare presents continued positive findings from firs..
PU
10/21S.Korea sticks to flu vaccine plan despite safety fears after 13 deaths
RE
10/21Wall Street banks see rare payday bonanza in India despite pandemic
RE
10/21Number of South Koreans dying after flu shot rises, prompts vaccine worries
RE
10/21GLAXOSMITHKLINE : JP Morgan gives a Neutral rating
MD
10/21GLAXOSMITHKLINE : ViiV Healthcare announces analysis showing no antiretroviral t..
PU
10/21GLAXOSMITHKLINE : GSK presents positive clinical data on maternal and older adul..
PU
10/21GSK to launch late-stage testing of syncytial virus vaccine
RE
10/16EXPLAINER : When will COVID-19 vaccines be generally available in the United Sta..
RE
10/16ViiV Healthcare receives positive CHMP opinion for long-acting regimen for th..
AQ
10/16GLAXOSMITHKLINE : ViiV Healthcare receives positive CHMP opinion for long-acting..
PU
10/15Sanofi reports positive animal test results for potential COVID-19 vaccine
RE
10/13Enzymatica and STADA extend agreement on ViruProtect to Russia, Poland, Ukrai..
AQ
10/13GLAXOSMITHKLINE : Goldman Sachs reiterates its Buy rating
MD
More news
News in other languages on GLAXOSMITHKLINE PLC
10/21GLAXOSMITHKLINE : JP Morgan conserve son opinion neutre
10/21JPMorgan belässt GlaxoSmithKline auf 'Neutral'
10/21GSK : essais concluants pour le vaccin anti-VRS
10/16GSK : un traitement du VIH avalisé par le CHMP
10/14Aktien Europa Schluss: Moderate Verluste - Starkes Pfund belastet London
More news
Analyst Recommendations on GLAXOSMITHKLINE PLC
More recommendations
Chart GLAXOSMITHKLINE PLC
Duration : Period :
GlaxoSmithKline plc Technical Analysis Chart | GSK | GB0009252882 | MarketScreener
Technical analysis trends GLAXOSMITHKLINE PLC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 1 806,25 GBX
Last Close Price 1 353,60 GBX
Spread / Highest target 73,6%
Spread / Average Target 33,4%
Spread / Lowest Target -17,3%
EPS Revisions
Managers
NameTitle
Emma N. Walmsley Chief Executive Officer & Executive Director
Jonathan Richard Symonds Non-Executive Chairman
Iain James Mackay Chief Financial Officer & Executive Director
Karenann K. Terrell Chief Digital & Technology Officer
Hal V. Barron Executive Director & Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
GLAXOSMITHKLINE PLC-23.91%88 545
JOHNSON & JOHNSON-1.33%378 942
ROCHE HOLDING AG-4.73%283 006
PFIZER INC.-4.31%206 049
MERCK & CO., INC.-14.16%197 458
NOVARTIS AG-16.89%186 106